Reactions 1680, p154 - 2 Dec 2017 Ototoxicity: case report A 50-year-old man developed ototoxicity during treatment with gentamicin [gentamycin]. The man, who had a history of hypertension and diabetes, underwent a promus stent implantation and a coronary angioplasty. However, a month later, he developed fever followed by acute left ventricular failure and cardiac arrest. Thereafter, due to development of occluded circumflex artery and coronary aneurysm noted at the site of stent implantation, stent removal was performed. Subsequently, he was started on protracted antibiotic therapy with IV gentamicin 80mg three times a day [duration of treatment to reaction onset not stated], ceftazidime and vancomycin for Pseudomonas aeruginosa and Staphylococcus warneri infection. During the treatment, he developed ototoxicity. The man’s gentamicin therapy was discontinued after two weeks. Other antibiotics were continued for a period of six weeks. He recovered completely. Author comment: "After two weeks the gentamycin was stopped as he showed oto-toxicity." Dalal JJ, et al. Coronary stent infection - A grave, avoidable complication. IHJ Cardiovascular Case Reports (CVCR) 1: 77-79, No. 2, 2017. Available from: URL: http://doi.org/10.1016/j.ihjccr.2017.07.002 - India 803285379 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera